NCT07191574

Brief Summary

Objective We investigated the value of stress cardiac magnetic resonance (CMR) imaging with vasodilators for predicting long-term all-cause mortality in patients with known or suspected ischemic heart disease, using data from a large 15-year registry. Materials and Methods A total of 5,552 consecutive patients with known or suspected ischemic heart disease were included in a registry. They had been referred by their attending cardiologists for clinically indicated stress CMR with vasodilators between 2001 and 2016. All patients provided written informed consent prior to undergoing CMR. At the time of the CMR, clinical characteristics and both segmental and global CMR findings were collected. The presence and extent of stress-induced ischemia were recorded. The study hypothesis is that the presence of ischemia detected by stress CMR is associated with increased long-term all-cause mortality. The study will also explore whether CMR-related revascularization (triggered by ischemia on CMR and performed within the following three months) is associated with reduced long-term mortality. Clinical and CMR data were collected prospectively. Event follow-up will be conducted retrospectively for the purposes of this project through a review of patients' electronic medical records, following approval by the institutional ethics committee. Expected Results This study aims to provide conclusive evidence regarding the utility of stress CMR in predicting the most serious clinical outcome: all-cause mortality. It will also offer valuable insights into the potential therapeutic implications of CMR findings in terms of mortality reduction, depending on test results and subsequent management strategies. The large patient registry enables us to retrospectively address these key clinical questions, contributing to a more rational use of stress cardiac magnetic resonance and a more personalized approach to patient care.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,552

participants targeted

Target at P75+ for all trials

Timeline
4mo left

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Jan 2025Sep 2026

Study Start

First participant enrolled

January 1, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2025

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

September 17, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 25, 2025

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Expected
Last Updated

September 25, 2025

Status Verified

September 1, 2025

Enrollment Period

1 month

First QC Date

September 17, 2025

Last Update Submit

September 24, 2025

Conditions

Keywords

Stress cardiac magnetic resonance

Outcome Measures

Primary Outcomes (1)

  • Number of Participants with All-cause Mortality as Assessed by Electronic Health Records.

    Primary: All-cause mortality, defined as death from any cause during long-term follow-up, assessed through retrospective review of electronic health records (ORION, ABUCASIS) and adjudicated by consensus of two independent cardiologists. Secondary: Cardiac death, defined as death due to acute myocardial infarction, congestive heart failure, malignant arrhythmias, or cardiac arrest, assessed with the same method. Exploratory: Revascularization related to CMR (procedures performed within 3 months after CMR and directly triggered by its results); myocardial ischemic burden (number of segments with perfusion defects during vasodilator stress CMR); left ventricular ejection fraction (percentage of end-diastolic volume ejected during systole); and myocardial necrosis extent (presence and extent of late gadolinium enhancement). Imaging outcomes analyzed using validated cardiovascular imaging software (Syngo, Siemens).

    up to 15 years

Study Arms (1)

Patients with known or suspected ischemic heart disease

Patients with known or suspected ischemic heart disease

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This is a retrospective registry that includes all consecutive patients referred by their responsible cardiologists for stress cardiac magnetic resonance imaging with vasodilators for clinical indication in the CMR Unit between January 2001 and December 2016.

You may qualify if:

  • known or suspected ischemic heart disease
  • stress vasodilator cardiac magnetic resonance imaging study
  • written informed consent to undergo the stress vasodilator cardiac magnetic resonance imaging study

You may not qualify if:

  • insufficient image quality
  • incomplete study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

INCLIVA Instituto de Investigación Sanitaria

Valencia, 46010, Spain

Location

MeSH Terms

Conditions

Myocardial Ischemia

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesVascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2025

First Posted

September 25, 2025

Study Start

January 1, 2025

Primary Completion

January 31, 2025

Study Completion (Estimated)

September 1, 2026

Last Updated

September 25, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

We consider that the individual data of each patient are not relevant for publication. We prefer to keep them anonymous.

Locations